MedPath

Telephone Versus Videoconference Communication for Remote Genetic Disclosure in the APOE4 Trial

Not Applicable
Completed
Conditions
Alzheimer Disease
Genetic Predisposition to Disease
Interventions
Other: Telephone remote genetic counseling
Other: Two-way videoconference remote genetic counseling
Registration Number
NCT02978729
Lead Sponsor
University of Pennsylvania
Brief Summary

The purpose of this study is to compare two methods for remote genetic counseling (telephone and two-way videoconferencing) for patients who are receiving disclosure of their APOE (apolipoprotein E) genotype. The target population will consist of males and females in the age range of 60-75 years who, as potential participants in a study (Generation Study), will need to receive genetic counseling and disclosure of APOE genotype. Subjects must be willing to receive genetic counseling and disclosure remotely. Subjects must be willing to be randomized to either telephone arm or videoconference arm.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
613
Inclusion Criteria
  1. Eligible to participate in the Generation Study
  2. Ability to provide consent
  3. Ability to communicate and hear in English
Read More
Exclusion Criteria
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TelephoneTelephone remote genetic counselingTelephone telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via telephone. The participant will be in a private room at the study site. Telephone sessions will utilize a private phone line. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
VideoconferenceTwo-way videoconference remote genetic counselingTwo-way videoconferencing telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via two-way videoconferencing. The participant will be in a private room at the study site. Videoconferencing sessions will utilize tablets or laptops with web cameras and secure/confidential software for teleconferencing. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
Primary Outcome Measures
NameTimeMethod
Satisfaction with genetic counseling services as measured by the Satisfaction with Genetic Services Scale2-7 days
Satisfaction with genetic counseling services as measured by the Satisfaction with Remote Counseling Scale2-7 days
Secondary Outcome Measures
NameTimeMethod
Knowledge of Genetic Disease as measured by the Cancer Genetics Knowledge Scale2-7 days, 6 weeks, 6 months, 12 months
Disease-specific distress as measured by the Impact of Events Scale2-7 days, 6 weeks, 6 months, 12 months
Responses to Genetic Testing as measured by the Impact of Genetic Testing for Alzheimer's disease (IGT-AD) scale2-7 days, 6 weeks, 6 months, 12 months
Perceived risk of Alzheimers Disease as measured by questionnaire items measuring perceived risk in quantitative, qualitative, and relative terms2-7 days, 6 weeks, 6 months, 12 months
Depression as measured by the GDS Short Form2-7 days, 6 weeks, 6 months, 12 months
Anxiety as measured by the Mini State Trait Anxiety Inventory (mSTAI):2-7 days, 6 weeks, 6 months, 12 months
Knowledge of Genetic Disease as measured by the ClinSeq Knowledge Scale2-7 days, 6 weeks, 6 months, 12 months
© Copyright 2025. All Rights Reserved by MedPath